Adherence to systemic therapy is essential for effectively managing atopic dermatitis (AD), however, new study findings published in Cureus highlights the need for streamlined treatment regimens and ...

Objectives Atopic dermatitis is a chronic, relapsing, inflammatory skin disease that impacts patients’ quality of life and imposes substantial economic burdens on their families. Acupuncture holds ...

Potential systemic adverse effects include growth ... Some clinicians may choose to initiate treatment of atopic dermatitis with topical corticosteroids and make a transition to topical ...

AD can be treated by various topical, systemic, and/or physical agents ... Because psychological stress may exacerbate atopic dermatitis, psychotherapy may help alleviate AD in selected patients.

Educational interventions for patients, including both in-person and online methods, significantly reduced atopic dermatitis (AD) severity.

Consulting with a dermatologist can help patients determine the most suitable treatment plan based on their needs and budget. In the ongoing battle against atopic dermatitis, crisaborole two percent ...

With over 1,100 subjects enrolled across 39 clinical study sites, the company is developing and validating the study.

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. Until recently, adequate systemic treatment options for patients with moderate-to-severe AD were limited.

17, 2024 -- The FDA last week approved Nemluvio for treating moderate to severe atopic dermatitis ... before starting treatment. Also, patients must notify their doctor about all medications ...

Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today provided an update on its test currently in development for use in patients diagnosed with ...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today provided an update on its test currently in development for use in ...